Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-selection study of GSK2248761 in antiretroviral-experienced adults with HIV-1 infection
2010-018532-40Phase 2Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of Fosdevirine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ViiV Healthcare. Primary endpoint: Proportion with HIV-1 RNA <50 copies/mL at Week 16. Started Sep 2010; status: completed.
02
Drugs
Fosdevirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-018532-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018532-40.